Alert icon

To align with industry best practices for security and data integrity, Project Data Sphere is requiring users to upgrade their browsers to one that supports encryption protocol TLS 1.2 by December 15, 2017. On that date, Project Data Sphere will disable support of browsers that permit SSL 3.0/TLS 1.0. To prevent any disruption to your access to Project Data Sphere, you must take action.
This browser was not recognized and may not be compatible with TLS 1.2 or higher. Please check with the browser's developer to confirm.
To view information about this, please visit the FAQ. If you have any further questions, please contact us.

Back to the List
Type(s) of Cancer
Ovarian
Study Phase
Phase 3
Study Completion Date
2015-12-01
NCT01167712Uploaded 07-03-2024
Access via NCI by Request
PDS UID: nci-data-546
GOG-0262: A Phase III Trial of Every-3-Weeks Paclitaxel Versus Dose Dense Weekly Paclitaxel in Combination With Carboplatin With or Without Concurrent and Consolidation Bevacizumab (NSC #704865) in the Treatment of Primary Stage II, III or IV Epithelial Ovarian, Peritoneal or Fallopian Tube Cancer and ACRIN 6695: Perfusion CT Imaging to Evaluate Treatment Response in Patients Participating in GOG-0262
Provider Information
Provider Data DescriptionThere are 5 data submissions associated with PMID 26933849. This dataset contains the treatment comparison between dose-dense versus weekly Paclitaxel and Carboplatin in trial NCT01167712.
SponsorNational Cancer Institute (NCI)
Data ProviderNational Cancer Institute
Clinical Trials.gov Information
Brief SummaryThis phase III clinical trial studies two different dose schedules of paclitaxel to see how well they work in combination with carboplatin with or without bevacizumab in treating patients with stage II, III or IV ovarian epithelial cancer, primary peritoneal cancer, or fallopian tube cancer. Drugs used in chemotherapy, such as paclitaxel and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Bevacizumab is a type of drug called a monoclonal antibody and blocks tumor growth by stopping the growth of blood vessels that tumors need to grow. It is not yet known whether giving paclitaxel with combination chemotherapy once every three weeks is more effective than giving paclitaxel once a week in treating patients with ovarian, primary peritoneal, or fallopian tube cancer.
ConditionsFallopian Tube Endometrioid Adenocarcinoma
Fallopian Tube Mucinous Adenocarcinoma
Fallopian Tube Transitional Cell Carcinoma
Ovarian Brenner Tumor
Ovarian Clear Cell Adenocarcinofibroma
Ovarian Endometrioid Adenocarcinoma
Ovarian Mucinous Adenocarcinoma
Ovarian Seromucinous Carcinoma
Ovarian Serous Adenocarcinoma
Ovarian Transitional Cell Carcinoma
Ovarian Undifferentiated Carcinoma
Primary Peritoneal Serous Adenocarcinoma
Stage IIA Fallopian Tube Cancer AJCC v6 and v7
Stage IIA Ovarian Cancer AJCC V6 and v7
Stage IIB Fallopian Tube Cancer AJCC v6 and v7
Stage IIB Ovarian Cancer AJCC v6 and v7
Stage IIC Fallopian Tube Cancer AJCC v6 and v7
Stage IIC Ovarian Cancer AJCC v6 and v7
Stage IIIA Fallopian Tube Cancer AJCC v7
Stage IIIA Ovarian Cancer AJCC v6 and v7
Stage IIIA Primary Peritoneal Cancer AJCC v7
Stage IIIB Fallopian Tube Cancer AJCC v7
Stage IIIB Ovarian Cancer AJCC v6 and v7
Stage IIIB Primary Peritoneal Cancer AJCC v7
Stage IIIC Fallopian Tube Cancer AJCC v7
Stage IIIC Ovarian Cancer AJCC v6 and v7
Stage IIIC Primary Peritoneal Cancer AJCC v7
Stage IV Fallopian Tube Cancer AJCC v6 and v7
Stage IV Ovarian Cancer AJCC v6 and v7
Stage IV Primary Peritoneal Cancer AJCC v7
Intervention TypeBiological: Bevacizumab
Drug: Carboplatin
Procedure: Computed Tomography
Drug: Paclitaxel
Procedure: Therapeutic Conventional Surgery
Drug(s)Drug: Carboplatin
Drug: Paclitaxel
Total Enrolled692
RandomizationNon Randomized
Blinding MethodNone
Arms InterventionArm I (adjuvant chemotherapy suboptimally debulked) - Experimental
Arm II (neoadjuvant chemotherapy) - Experimental
Secondary IDNCI-2011-03812
PubMed (PMID)26933849
Collaborator(s)NRG Oncology
Region(s)United States
Canada
Korea, Republic of
Age Range18 Years and older (ADULT, OLDER_ADULT)
Files: NCT01167712-D1
Data DictionaryNCT01167712-D1-Data-Dictionary.pdf
DATANCT01167712-D1-Dataset.csv
OTHERREADME.pdf
Files: NCT01167712-D2
Data DictionaryNCT01167712-D2-Data-Dictionary.pdf
DATANCT01167712-D2-Dataset.csv
OTHERREADME.pdf
Files: NCT01167712-D3
Data DictionaryNCT01167712-D3-Data-Dictionary.pdf
DATANCT01167712-D3-Dataset.csv
OTHERREADME.pdf
Files: NCT01167712-D4
Data DictionaryNCT01167712-D4-Data-Dictionary.pdf
DATANCT01167712-D4-Dataset.csv
OTHERREADME.pdf
Files: NCT01167712-D5
Data DictionaryNCT01167712-D5-Data-Dictionary.pdf
DATANCT01167712-D5-Dataset.csv
OTHERREADME.pdf
© 2024 Project Data Sphere
All rights reserved
Privacy PolicyTerms of Use